InflaRx N.V. (IFRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $172.42M
Last updated: Nov 17, 2026 at 4:10 PM ET
InflaRx N.V. (IFRX) Statistics
InflaRx (IFRX) has a market cap of $172.42M. Its share count is up 116.35% from a year earlier. Revenue fell 154.00% over the last 12 months from the 12 months before.
Total Valuation
| Market Cap | $172.42M |
|---|---|
| Latest price (Nov 17, 2026) | $1.15 |
Key Dates
The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 1.0x |
|---|---|
| P/TBV Ratio | 1.0x |
Price Statistics
The stock is down 14.81% over 52 weeks and trades 30.30% below its 50-day average.
| Beta (1Y) | 1.51 |
|---|---|
| 52-Week Change | -14.81% |
| 1-Month Change | -20.69% |
| 3-Month Change | -45.75% |
| 6-Month Change | -51.48% |
| 5-Year Change | -60.85% |
| Total Return (1Y) | -14.81% |
| Total Return (3Y CAGR) | -8.27% |
| Total Return (5Y CAGR) | -24.68% |
| Return vs SPY (1Y) | -21.01% |
| Max Drawdown (1Y) | -58.03% |
| Max Drawdown (3Y) | -72.94% |
| Sharpe Ratio (1Y) | -0.12 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $1.65 |
| 200-Day Average | $1.66 |
| 52-Week Range | $0.80 to $2.95 |
| RSI (14 Days) | 30.8 |
| Average Volume (20 Days) | 1.05M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.26x current liabilities.
| Current Ratio | 7.26x |
|---|---|
| Quick Ratio | 7.26x |
| Interest Coverage | -491.74x |
Returns and Efficiency
Return on equity is -20.76% over the last 12 months, against a 5-year average of -60.63%.
| Return on Equity (ROE) | -20.76% |
|---|---|
| Return on Assets (ROA) | -18.54% |
| Return on Capital Employed (ROCE) | -20.23% |
| ROE (5Y Average) | -60.63% |
| ROA (5Y Average) | -48.81% |
| ROIC (5Y Average) | -59.71% |
| Receivables Turnover | 0.02x |
Scores
IFRX has an Altman Z-Score of 1.94, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.94 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was EUR -33.93K over the last 12 months.
| Revenue | EUR -33.93K |
|---|---|
| Revenue Growth (YoY) | -154.00% |
| Gross Profit | EUR -5.07M |
| Operating Income | EUR -32.66M |
| Pretax Income | EUR -29.32M |
| Net Income | EUR -29.32M |
| EBITDA | EUR -28.91M |
| EBIT | EUR -29.26M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 89.33% of the EUR 161.32M in total assets.
| Working Capital | EUR 104.33M |
|---|---|
| Shareholder Equity | EUR 144.10M |
| Tangible Book Value | EUR 143.98M |
| Total Assets | EUR 161.32M |
| Total Liabilities | EUR 17.22M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After EUR 103.47K of capital spending, operating cash flow left EUR -18.92M of free cash flow.
| Operating Cash Flow | EUR -18.82M |
|---|---|
| Capital Expenditures | EUR 103.47K |
| Free Cash Flow | EUR -18.92M |
| Depreciation and Amortization | EUR 355.80K |
Trailing 12 months through Sep 30, 2026.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About IFRX
What is IFRX's market cap?
InflaRx has a market cap of $172.42M.
How many shares of IFRX are outstanding?
InflaRx has 147.37M shares outstanding. The count is up 116.35% from a year earlier.
Does IFRX pay a dividend?
No. InflaRx does not pay a dividend.
IFRX pages: Overview, Charting, Financials, Statistics, Competitors